Sep 30, 2022

Revolution Medicines Q3 2022 Earnings Report

Total Revenue
$3.36M
Previous year: $1.1M
+204.8%
EPS
-$0.87
Previous year: -$0.72
+20.8%
R&D Expenses
$69.5M
G&A Expenses
$10.4M
Gross Profit
-$66.1M
Previous year: -$45.4M
+45.7%
Cash and Equivalents
$179M
Previous year: $129M
+38.5%
Free Cash Flow
-$55.3M
Previous year: -$37M
+49.2%
Total Assets
$826M
Previous year: $735M
+12.4%

Revolution Medicines

Revolution Medicines